Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B

Cristiana Barbera, Flavia Bortolotti, Carlo Crivellaro, Alessandra Coscia, Lucia Zancan, Paolo Cadrobbi, Gabriella Nebbia, Maria Nazarena Pillan, Loredana Lepore, Teresa Parrella, Giuseppe Dastoli, Maurizia R. Brunetto, Ferruccio Bonino

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

We conducted a prospective controlled study of the efficacy of recombinant interferon-α2a in 77 children (44 boys, 33 girls, mean age 8 yr) with chronic hepatitis B. All patients had seropositive results for HBeAg and hepatitis B virus DNA; 52 had chronic persistent or nonspecific reactive hepatitis, and 25 had mild active hepatitis. Twenty-one children (group 1) received recombinant interferon-α2a 7.5 megaunits/m2 three times weekly for 6 mo, 19 children (group 2) received megaunits/m2 on the same schedule and 37 (group 3) remained untreated. At 6 mo, HBe antigen-to-antibody seroconversion associated with biochemical remission was seen in 24% of patients in group 1, 5% in group 2 and 3% in group 3 (p <0.05 vs. group 1). At 18 mo, seroconversion rates were 30% in group 1, 21% in group 2 and 13.5% in group 3. These results suggest that a course of recombinant interferon-α2a accelerates HBeAg-HBe antibody seroconversion in children. High baseline ALT levels were sensitive predictors of seroconversion in both treated and untreated patients. In contrast, baseline IgM HBc antibody levels influenced the rate of anti-HBe seroconversion only in untreated patients. These findings suggest that, in children as well as in adults, recombinant interferon-α2a favors the clearance of hepatitis B virus replication, enhancing the host antiviral immunoresponse.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalHepatology
Volume20
Issue number2
Publication statusPublished - Aug 1994

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Interferons
Hepatitis B virus
Hepatitis
Antibodies
Virus Replication
Antiviral Agents
Immunoglobulin M
Appointments and Schedules
Seroconversion
Prospective Studies
Antigens
DNA

ASJC Scopus subject areas

  • Hepatology

Cite this

Barbera, C., Bortolotti, F., Crivellaro, C., Coscia, A., Zancan, L., Cadrobbi, P., ... Bonino, F. (1994). Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology, 20(2), 287-290.

Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. / Barbera, Cristiana; Bortolotti, Flavia; Crivellaro, Carlo; Coscia, Alessandra; Zancan, Lucia; Cadrobbi, Paolo; Nebbia, Gabriella; Pillan, Maria Nazarena; Lepore, Loredana; Parrella, Teresa; Dastoli, Giuseppe; Brunetto, Maurizia R.; Bonino, Ferruccio.

In: Hepatology, Vol. 20, No. 2, 08.1994, p. 287-290.

Research output: Contribution to journalArticle

Barbera, C, Bortolotti, F, Crivellaro, C, Coscia, A, Zancan, L, Cadrobbi, P, Nebbia, G, Pillan, MN, Lepore, L, Parrella, T, Dastoli, G, Brunetto, MR & Bonino, F 1994, 'Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B', Hepatology, vol. 20, no. 2, pp. 287-290.
Barbera C, Bortolotti F, Crivellaro C, Coscia A, Zancan L, Cadrobbi P et al. Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology. 1994 Aug;20(2):287-290.
Barbera, Cristiana ; Bortolotti, Flavia ; Crivellaro, Carlo ; Coscia, Alessandra ; Zancan, Lucia ; Cadrobbi, Paolo ; Nebbia, Gabriella ; Pillan, Maria Nazarena ; Lepore, Loredana ; Parrella, Teresa ; Dastoli, Giuseppe ; Brunetto, Maurizia R. ; Bonino, Ferruccio. / Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. In: Hepatology. 1994 ; Vol. 20, No. 2. pp. 287-290.
@article{2cdc43ef1c2443eb9b3deb92411bb4e0,
title = "Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B",
abstract = "We conducted a prospective controlled study of the efficacy of recombinant interferon-α2a in 77 children (44 boys, 33 girls, mean age 8 yr) with chronic hepatitis B. All patients had seropositive results for HBeAg and hepatitis B virus DNA; 52 had chronic persistent or nonspecific reactive hepatitis, and 25 had mild active hepatitis. Twenty-one children (group 1) received recombinant interferon-α2a 7.5 megaunits/m2 three times weekly for 6 mo, 19 children (group 2) received megaunits/m2 on the same schedule and 37 (group 3) remained untreated. At 6 mo, HBe antigen-to-antibody seroconversion associated with biochemical remission was seen in 24{\%} of patients in group 1, 5{\%} in group 2 and 3{\%} in group 3 (p <0.05 vs. group 1). At 18 mo, seroconversion rates were 30{\%} in group 1, 21{\%} in group 2 and 13.5{\%} in group 3. These results suggest that a course of recombinant interferon-α2a accelerates HBeAg-HBe antibody seroconversion in children. High baseline ALT levels were sensitive predictors of seroconversion in both treated and untreated patients. In contrast, baseline IgM HBc antibody levels influenced the rate of anti-HBe seroconversion only in untreated patients. These findings suggest that, in children as well as in adults, recombinant interferon-α2a favors the clearance of hepatitis B virus replication, enhancing the host antiviral immunoresponse.",
author = "Cristiana Barbera and Flavia Bortolotti and Carlo Crivellaro and Alessandra Coscia and Lucia Zancan and Paolo Cadrobbi and Gabriella Nebbia and Pillan, {Maria Nazarena} and Loredana Lepore and Teresa Parrella and Giuseppe Dastoli and Brunetto, {Maurizia R.} and Ferruccio Bonino",
year = "1994",
month = "8",
language = "English",
volume = "20",
pages = "287--290",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Recombinant interferon-α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B

AU - Barbera, Cristiana

AU - Bortolotti, Flavia

AU - Crivellaro, Carlo

AU - Coscia, Alessandra

AU - Zancan, Lucia

AU - Cadrobbi, Paolo

AU - Nebbia, Gabriella

AU - Pillan, Maria Nazarena

AU - Lepore, Loredana

AU - Parrella, Teresa

AU - Dastoli, Giuseppe

AU - Brunetto, Maurizia R.

AU - Bonino, Ferruccio

PY - 1994/8

Y1 - 1994/8

N2 - We conducted a prospective controlled study of the efficacy of recombinant interferon-α2a in 77 children (44 boys, 33 girls, mean age 8 yr) with chronic hepatitis B. All patients had seropositive results for HBeAg and hepatitis B virus DNA; 52 had chronic persistent or nonspecific reactive hepatitis, and 25 had mild active hepatitis. Twenty-one children (group 1) received recombinant interferon-α2a 7.5 megaunits/m2 three times weekly for 6 mo, 19 children (group 2) received megaunits/m2 on the same schedule and 37 (group 3) remained untreated. At 6 mo, HBe antigen-to-antibody seroconversion associated with biochemical remission was seen in 24% of patients in group 1, 5% in group 2 and 3% in group 3 (p <0.05 vs. group 1). At 18 mo, seroconversion rates were 30% in group 1, 21% in group 2 and 13.5% in group 3. These results suggest that a course of recombinant interferon-α2a accelerates HBeAg-HBe antibody seroconversion in children. High baseline ALT levels were sensitive predictors of seroconversion in both treated and untreated patients. In contrast, baseline IgM HBc antibody levels influenced the rate of anti-HBe seroconversion only in untreated patients. These findings suggest that, in children as well as in adults, recombinant interferon-α2a favors the clearance of hepatitis B virus replication, enhancing the host antiviral immunoresponse.

AB - We conducted a prospective controlled study of the efficacy of recombinant interferon-α2a in 77 children (44 boys, 33 girls, mean age 8 yr) with chronic hepatitis B. All patients had seropositive results for HBeAg and hepatitis B virus DNA; 52 had chronic persistent or nonspecific reactive hepatitis, and 25 had mild active hepatitis. Twenty-one children (group 1) received recombinant interferon-α2a 7.5 megaunits/m2 three times weekly for 6 mo, 19 children (group 2) received megaunits/m2 on the same schedule and 37 (group 3) remained untreated. At 6 mo, HBe antigen-to-antibody seroconversion associated with biochemical remission was seen in 24% of patients in group 1, 5% in group 2 and 3% in group 3 (p <0.05 vs. group 1). At 18 mo, seroconversion rates were 30% in group 1, 21% in group 2 and 13.5% in group 3. These results suggest that a course of recombinant interferon-α2a accelerates HBeAg-HBe antibody seroconversion in children. High baseline ALT levels were sensitive predictors of seroconversion in both treated and untreated patients. In contrast, baseline IgM HBc antibody levels influenced the rate of anti-HBe seroconversion only in untreated patients. These findings suggest that, in children as well as in adults, recombinant interferon-α2a favors the clearance of hepatitis B virus replication, enhancing the host antiviral immunoresponse.

UR - http://www.scopus.com/inward/record.url?scp=0028023095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028023095&partnerID=8YFLogxK

M3 - Article

C2 - 8045488

AN - SCOPUS:0028023095

VL - 20

SP - 287

EP - 290

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -